Vol. 3 No. 4 (2023)
Reimbursement Reviews

Deferiprone (Ferriprox)

decorative image

Published April 27, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses deferiprone (Ferriprox), 1,000 mg oral tablets and 100 mg/mL oral solution.
  • Indication: The treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.